Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT05092841 |
| Consolidated Lead Sponsor | Tasly GeneNet Pharmaceuticals Co |
| Therapeutic Condition Cohort | Rare Genetic, Women's Health, and Other |
| Clinical Trial Phase | Phase III |
| Overall Recruitment Status | COMPLETED |
| Registered Enrollment | 176 participants (ACTUAL) |
| Registered Start Date | 2021-09-28 |
| WhyStopped Classification | Not Stopped |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| Peking University Third Hospital | Beijing, China | Open Hospital Dossier -> |
| Xuanwu Hospital Capital Medical University | Beijing, China | Open Hospital Dossier -> |
| The First Bethune Hospital of Jilin University | Changchun, China | Open Hospital Dossier -> |
| The Third Xiangya Hospital of Central South University | Changsha, China | Open Hospital Dossier -> |
Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.